Insights from 2023 ASCO® Annual Meeting

 

Insights from 2023 ASCO® Annual Meeting
W

ASCO® 2023 Insights: "Phase 3 TRIDENT Study (EF-32) - Tumor Treating Fields Concomitant With CRT and Maintenance TTFields Therapy/Temozolomide in Newly Diagnosed Glioblastoma"

By Insights from 2023 ASCO® Annual Meeting FEATURING Wenyin Shi
By Insights from 2023 ASCO® Annual Meeting FEATURING Wenyin Shi
94 views
June 8, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

20:25
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam

Featured Video

21:17
Janssen Oncology

The Man Cave

Feat. J. Hamilton, M. Fabrizio, M. Taha
CNS
21:24
Insights from 2023 ASCO® Annual Meeting

Breaking Bad Barriers: Brain-Penetrant Small Molecule Inhibitors

Feat. A. Shergill
06:05
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Phase 3 INDIGO Study Updates - Vorasideni…

Feat. M. Preusser
04:02
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Phase 3 TRIDENT Study (EF-32) - Tumor Tre…

Feat. W. Shi